Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267308 | 0.90 | CYP11B2 (0.46) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL24753361 | 0.89 | HPGD (0.49) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL20461030 | 0.89 | HPGD (0.49) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL1474868 | 0.87 | USP2 (0.49) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL25547105 | 0.85 | GPR119 (0.50) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL29024806 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL29326315 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL16969327 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL2343400 | 0.85 | GPR119 (0.50) | USP2SMN1; SMN2GPR119EPHX2HPGD | |
| SCHEMBL623537 | 0.85 | GPR119 (0.50) | USP2SMN1; SMN2GPR119EPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4008720-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS TLR8 AGONIST | BeiGene, Ltd. (KY) | 2022-06-08 | — | — | EP | disclosed |
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | USP2 32/4885SMN1; SMN2 3149/4885GPR119 4358/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GPR119 2426/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | USP2 3233/4885SMN1; SMN2 4812/4885GPR119 2121/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GPR119 2426/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GPR119 2426/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885GPR119 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.